ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "SLE"

  • Abstract Number: 56 • 2015 ACR/ARHP Annual Meeting

    Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)

    Kathryn Jackson, Theresa Walunas, Anh Chung and Rosalind Ramsey-Goldman, Northwestern University, Chicago, IL

    Background/Purpose: Care fragmentation is associated with poor health outcomes and is hard to assess in a single-site data registry. The Chicago HealthLNK Data Repository (CHDR)…
  • Abstract Number: 753 • 2015 ACR/ARHP Annual Meeting

    Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy

    Jakub Zavada1, Michal Uher2, Radka Svobodova3, Marta Olejarova1, Marketa Husakova3, Hana Ciferska3, Hana Hulejova4, Ladislav Senolt3 and Jiri Vencovsky3, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic

    Background/Purpose: The aim of this study was to examine whether circulating levels of  the pro-inflammatory glycoprotein tenascin-C (TSC) are useful as an activity-specific or predictive…
  • Abstract Number: 1070 • 2015 ACR/ARHP Annual Meeting

    CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE

    Sarit sekhar Pattanaik1, Aditya kumar Panda2, Rashmi ranjan Sahoo1, Rina Tripathy3 and Bidyut kumar Das1, 1Medicine, SCB Medical College, Cuttack, India, 2Centre for Life science, Central University of Jharkand, Ranchi, India, 3Biochemistry, SCB Medical College, Cuttack, India

    Background/Purpose: Cluster of differentiation 14 (CD14) plays an important role in innate immune system as a co-receptor in TLRs (2, 4, 7 and 9) signaling.…
  • Abstract Number: 1801 • 2015 ACR/ARHP Annual Meeting

    Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice

    Syed Mahmood Shah, Michelle Petri and Hendrik Scholl, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: The risk of end-stage retinopathy (bull’s eye maculopathy) from hydroxychloroquine (HCQ) is low (0.65%, Wolfe and Marmor, 2010). With recent advances in retinal structure…
  • Abstract Number: 2071 • 2015 ACR/ARHP Annual Meeting

    Urinary Osteoprotegerin As Biomarker of Lupus Nephritis Disease Activity: Cross Sectional and Longitudinal Study

    Ranjan Gupta1, Amita Aggarwal2, Sudhir sinha3, Liza Rajasekhar4, Akhilesh Yadav1, Priyanka Gaur1, Ramnath Misra2 and Virsingh Negi5, 1Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3Department of Biochemistry, CSIR-central drug research institute, Lucknow, India, 4Department of Rheumatology, Nizam Institute of Medical Sciences, Hyderabad, India, 5Department of Clinical Immunology, JIPMER, Puducherry, India

    Background/Purpose: Urinary biomarkers may help in identification, treatment and assessment of response to therapy in patients with lupus nephritis (LN). Osteoprotegerin (OPG) is produced by…
  • Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting

    Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus

    Tianfu Wu1, Huihua Ding2, Cristina Arriens3, Chungwen Wei4, Jennifer H. Anolik5, David R. Karp3, Nancy J. Olsen6, Michelle Petri7, Ignacio Sanz4, Ramesh Saxena8 and Chandra Mohan2, 1Department of Biomedical Engineering, University of Houston, Houston, TX, 2Biomedical Engineering, University of Houston, Houston, TX, 3Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 4Rheumatology, Emory University, Atlanta, GA, 5University of Rochester Medical Center, Rochester, NY, 6Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, 7Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, 8Nephrology, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
  • Abstract Number: 88 • 2015 ACR/ARHP Annual Meeting

    Integrating Evidence for Genetic Association and Natural Selection Helps Detect New Systemic Lupus Erythematosus Risk Loci in African-Americans

    Paula S. Ramos1, Satria Sajuthi2, Jasmin Divers3, Kenneth M. Kaufman4, Uma Nayak5, Wei-Min Chen5, Kelly J. Hunt6, Diane L. Kamen7, Gary S. Gilkeson8, Jyotika K. Fernandes7, Ida J. Spruill9, Robert P. Kimberly10, John B. Harley11, W. Timothy Garvey12, Michèle M. Sale13 and Carl D. Langefeld2, 1Department of Medicine, Medical University of South Carolina, Charleston, SC, 2Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 3Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 4Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Public Health Sciences, University of Virginia, Charlottesville, VA, 6Public Health Sciences, Medical University of South Carolina, Charleston, SC, 7Medicine, Medical University of South Carolina, Charleston, SC, 8Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 9Nursing, Medical University of South Carolina, Charleston, SC, 10Medicine, Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 11Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 12Department of Nutrition Sciences and Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL, 13Department of Medicine and Center for Public Health Genomics, University of Virginia, Charlottesville, VA

    Background/Purpose: In many rheumatologic and autoimmune diseases African Americans (AA) have a higher prevalence and greater disease severity than other ethnicities. We posit that population-specific…
  • Abstract Number: 758 • 2015 ACR/ARHP Annual Meeting

    Dominican Patients with Systemic Lupus Erythematosus Residing in New York City Have a Higher SLICC/ACR Damage Index Than Those in the Dominican Republic

    Laura Geraldino-Pardilla1, Ivonne Canto2, Thania Perez3, Jossiell Then2, Esthela Loyo4 and Anca D. Askanase5, 1Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Rheumatology, Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago, Dominican Republic, 3Columbia University, College of Physicians & Surgeons, New York, NY, 4Rheumatology, Hospital Regional Universitario, Santiago, Dominican Republic, 5Department of Medicine Rhemuatology, Colombia University, New York, NY

    Background/Purpose: Higher accrual of damage has been reported in Hispanics with systemic lupus erythematosus (SLE) in the United States. This study was initiated to evaluate…
  • Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting

    Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE

    Robert W Hoffman1, Joan T Merrill2, Marta E. Marta Alarcón Riquelme3, Michelle Petri4, Ernst R Dow5, Eric Nantz6, Laura K Nisenbaum5, Krista M Schroeder6, Wendy J Komocsar6, Narayanan B Perumal5, Matthew D Linnik6, Guilherme V Rocha6 and Richard E Higgs6, 1Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, 2OMRF, Oklahoma, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, 5Eli Lilly and Company, Indiananpolis, IN, 6Eli Lilly and Company, Indianapolis, IN

    Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
  • Abstract Number: 1811 • 2015 ACR/ARHP Annual Meeting

    Depression and Progression of Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus

    April Jorge1, Apinya Lertratanakul2, Julia (Jungwha) Lee3, William Pearce1, David McPherson4, Trina Thompson5, Emma Barinas-Mitchell6 and Rosalind Ramsey-Goldman1, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, IL, 3Department of Preventive Medicine, Biostatistics Collaboration Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 4University of Texas Health Science Center, Houston, TX, 5Saint Francis University, Ebensburg, PA, 6University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Women with SLE have an increased incidence of premature cardiovascular disease (CVD). Depression is also common among SLE patients. A relationship between depression and…
  • Abstract Number: 2081 • 2015 ACR/ARHP Annual Meeting

    The SLE Workshop: An Evaluation of a Long-Standing Hospital-Based Psychoeducational Program

    Melissa T. Flores1, Roberta Horton1, Jillian A. Rose1, Stephen A. Paget2 and Michael Lockshin3, 1Social Work Programs, Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Hospital for Special Surgery, New York, NY, 3Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY

    Background/Purpose: An evaluation was conducted of a monthly hospital-based psychoeducational support group, ongoing since 1985, for people with lupus. Each 2-hour session begins with a…
  • Abstract Number: 3085 • 2015 ACR/ARHP Annual Meeting

    Platelet Activation and Endothelial Reactivity in the Pathogenesis of Tissue Inflammation/Injury in Systemic Lupus Erythematosus

    Robert Clancy1, Sokha Nhek2, Jonathan Newman3, Janet Nwaukoni1, Sara Rasmussen4, Jill P. Buyon1, Maya Rubin5, Kristen Lee1 and Jeffrey Berger5, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2New York University School of Medicine, New York, NY, 3Medicine, New York University School of Medicine, New York, NY, 4Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 5Medicine, Division of Cardiology, New York University School of Medicine, New York, NY

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk for widespread endothelial dysfunction, vascular thromboses, and premature cardiovascular disease.  Enhanced platelet activation and…
  • Abstract Number: 94 • 2015 ACR/ARHP Annual Meeting

    NGS Panel for the Detection of Monogenic SLE in Children: Initial Results

    Alexandre Belot1, Gillian Rice2, Anne-Laure Mathieu1, Brigitte Bader-Meunier3, Thierry Walzer1, Tracy A. Briggs2, James O'Sullivan4, Simon Wiliams5, Michael W. Beresford6, Yanick Crow2,7 and GENIAL Investigators, UK JSLE Study Group, 1INSERM U1111, Lyon, France, 2Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 3Pediatric Rheumatology & Immunology, Necker hospital, Imagine Institution, Paris, France, 4University of Manchester, Manchester, United Kingdom, 5University of Manchester, Manchester, France, 6Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 7Neuroinflammation, Institut Imagine, Paris, France

    Background/Purpose: Next generation sequencing (NGS) represents a revolution in the field of molecular medicine, and offers a new approach to deciphering the pathogenesis of complex…
  • Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting

    Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays

    John Conklin1, Basil Jones2, Tyler O'Malley3, Duncan Poling4, JoAnne Ligayon5, Leilani Wolover6, Ying Qu7, Claudia Ibarra8, Puja Chitkara9 and Thierry Dervieux3, 11261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 2Exagen Diagnostics, Vista, CA, 3Research and Development, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics Inc., Vista, CA, 5Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, 6Research and Development, Exagen Diagnostics, Inc., Vista, CA, 7Exagen Diagnostic Inc, Vista, CA, 8Clinical Laboratory, Exagen Diagnostics, Vista, CA, 9Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA

    Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
  • Abstract Number: 1074 • 2015 ACR/ARHP Annual Meeting

    DNA Methylation Patterns in Naïve CD4+ T Cells Identify Epigenetic Susceptibility Loci for Malar Rash and Discoid Rash in Systemic Lupus Erythematosus

    Paul Renauer1, Patrick Coit1, Matlock A. Jeffries2, Joan T. Merrill3, W Joseph McCune4, Kathleen Maksimowicz-McKinnon5 and Amr H. Sawalha6, 1Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Int Med/ Rheum, University of Michigan, Ann Arbor, MI, 5Rheumatology, Henry Ford Hospital, Detroit, MI, 6Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneous clinical manifestations, autoantibody production, and epigenetic dysregulation in T cells. We sought…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology